Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis.

ABSTRACT:

Background

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease group. Ibrutinib's monotherapy or combination therapy is effective in relapsed/refractory (R/R) DLBCL. However, the treatment response in R/R DLBCL varies from 15% to 90% with different regimens, and the tolerance remains controversial.

Areas of uncertainty

The efficacy and safety of ibrutinib monotherapy or combination therapy in patients with R/R DLBCL remain uncertain.

Data sources

The PubMed, CBM, MEDLINE, Cochrane Library, and Embase databases were searched from their inception to July 2021.

Therapeutic advances

The total complete remission rate (CRR) and overall response rate in R/R DLBCL patients treated with ibrutinib were 26% and 49%, respectively. The CRR of ibrutinib c

SUBMITTER: Li Y 

PROVIDER: S-EPMC11698132 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature